Core Viewpoint - CONMED Corporation has shown a positive performance with a 22.9% increase in shares since the last earnings report, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Financial Performance - Adjusted earnings per share (EPS) for Q4 2025 was $1.43, a 6.7% increase year over year, while GAAP EPS was 54 cents, down 50% from $1.08 in the previous year [2] - Total revenues for Q4 were $373.2 million, reflecting a 7.9% year-over-year increase, and full-year revenues reached $1.37 billion, up 5.2% from the previous year [3] Segment Performance - Orthopedic Surgery revenues in Q4 totaled $157.4 million, up 13.2% year over year, while General Surgery revenues were $215.8 million, up 4.3% [4] - U.S. General Surgery sales declined by 0.4%, but international sales increased by 16.3% [5] Geographical Results - Domestic revenues in Q4 were $206.2 million, up 1.4% year over year, while international revenues were $167 million, up 17% [6] Margin Analysis - Gross profit increased by 10.1% year over year to $218.3 million, with a gross margin of 58.5%, while total operating profit fell by 30.2% to $36.6 million [8][9] Financial Position - Cumulative net cash provided by operating activities at the end of Q4 2025 was $170.7 million, compared to $166.9 million a year ago [10] Guidance - For 2026, total reported revenues are expected to be between $1,345 million and $1,375 million, with adjusted EPS projected in the range of $4.30 to $4.45 [11] Estimate Trends - Since the earnings release, there has been a downward trend in estimates, with a consensus estimate shift of -11.71% [12] VGM Scores - CONMED has an average Growth Score of C, a Momentum Score of D, and a Value Score of A, resulting in an aggregate VGM Score of B [13] Outlook - Estimates for the stock have been trending downward, indicating a potential in-line return in the coming months, with a Zacks Rank of 3 (Hold) [14]

Core Insights - Grifols reported a net profit of 402 million euros ($473.96 million) for 2025, more than double the previous year's profit, driven by revenues of 7.5 billion euros, which increased by 7% year-over-year [1][1][1] - Adjusted EBITDA rose to 1.8 billion euros, aligning with market expectations [1][1][1] - The company has experienced a 25% decline in market value since January 2024 due to allegations from Gotham City Research regarding overstated earnings and understated debt, which Grifols has denied and is currently suing the fund [1][1][1]

Compute equals revenues. Every hyperscaler understands this that capex translates to compute. Compute with the right architecture translates to maximizing revenues and compute equals revenues.Without investing capacity today, without investing in compute, there cannot be revenue growth. And that I think everybody understands. Compute equals revenues.Choosing the right architecture is incredibly important. It's more than strategic. Now it directly affects their earnings. ...

Core Insights - Royal Gold, Inc. (RGLD) reported adjusted earnings per share of $1.92 in Q4 2025, missing the Zacks Consensus Estimate of $2.68, but showing an 18% year-over-year increase [1] - The company generated record revenues of $375 million in Q4, representing an 85% increase year-over-year [2] - RGLD's adjusted EBITDA margin was 82% in Q4, slightly down from 84% in the prior year [3] Financial Performance - RGLD's total revenues for 2025 reached $1.03 billion, up 43.2% year-over-year, driven by higher metal prices and contributions from various streams and assets [6] - Stream revenues for 2025 were $686.5 million, a 42% increase from 2024, while royalty revenues rose to $344 million from $236 million in the previous year [7] - The company's net cash from operating activities in Q4 was $242 million, up from $141 million in the same quarter last year, ending the year with cash and cash equivalents of $234 million [4][9] Cost and Margin Analysis - The cost of sales in Q4 was $50.8 million, a significant increase of 109.1% year-over-year, while general and administrative expenses surged 97.8% to $17.6 million [3] - Adjusted EBITDA for Q4 was $307 million, an 81.3% increase year-over-year, reflecting strong operational performance despite rising costs [3] Stock Performance - Over the past year, RGLD shares have increased by 84.3%, although this is lower than the industry's growth of 134.2% [8]

Core Insights - Exact Sciences Corporation (EXAS) reported a net loss of 21 cents per share in Q4 2025, which is higher than the loss of 6 cents in the same quarter last year, aligning with the Zacks Consensus Estimate [1] - For the full year 2025, earnings per share were 7 cents, a significant improvement from the loss of 23 cents in the previous year [1] EXAS Revenues - Q4 consolidated revenues reached $878.4 million, reflecting a 23.1% increase on a reported basis and 23% on a core revenue basis, surpassing the Zacks Consensus Estimate by 2.1% [2] - Full-year 2025 consolidated revenues totaled $3.25 billion, marking a 17.7% increase on a reported basis and 18% on a core revenue basis [2] - Following the earnings announcement, EXAS shares saw a slight increase of 0.07% [2] EXAS Q4 Segments in Detail - Screening revenues, which include laboratory service revenues from Cologuard and PreventionGenetics, amounted to $695.1 million, up 26% year over year [3] - Precision Oncology revenues, including laboratory service revenues from global Oncotype products and therapy selection products, were $183.2 million, reflecting a 14% year-over-year increase and 12% on a core basis [3] EXAS' Margins - Gross profit increased by 25% year over year to $615.8 million, with gross margin expanding by 106 basis points to 70.1% [4] - Research and development expenses rose by 96% year over year to $191.5 million, while sales and marketing expenses increased by 18% to $288.5 million [4] - General and administrative expenses grew by 14.1% year over year to $218 million [4] EXAS' Financial Update - At the end of Q4 2025, Exact Sciences had cash and cash equivalents and marketable securities totaling $964.7 million, down from $1.04 billion at the end of Q4 2024 [6] - Cumulative net cash provided by operating activities was $491.4 million, compared to $210.5 million in the previous year [6] Notable Developments - In Q4, Exact Sciences announced the first clinical study results from its Oncodetect molecular residual disease test in breast cancer, which showed favorable outcomes [10] - The company also reported pivotal clinical validation results from the ALTUS study during the quarter [10] - On November 19, 2025, Exact Sciences entered into a merger agreement with Abbott Laboratories, aiming for a close in Q2 2026, pending regulatory approvals [11]

Core Insights - Canadian Pacific Kansas City (CP) reported disappointing fourth-quarter 2025 results, with both earnings and revenues falling short of the Zacks Consensus Estimate [1][9] Financial Performance - Quarterly earnings, excluding 9 cents from non-recurring items, were 95 cents per share, missing the Zacks Consensus Estimate of 99 cents, but improved 3.3% year-over-year [2] - Operating revenues totaled $2.81 billion, which was below the Zacks Consensus Estimate of $2.86 billion, yet represented a 1.6% year-over-year increase [2] - Total Freight revenues per revenue ton miles grew by 1% year-over-year, while total Freight revenues per carload saw a slight decline of 0.1% [3] - Operating income increased by 3% year-over-year, and total operating expenses decreased by 0.2% year-over-year, leading to an operating ratio improvement of 80 basis points to 58.9% [3] Segment Performance - Freight revenues, which accounted for 98% of total revenues, increased by 1%, with notable segment performances: Grain (up 4%), Coal (up 3%), and Metals, minerals and consumer products (up 3%), while Potash (down 2%), Automotive (down 1%), and Energy, chemicals and plastics (down 2%) showed declines [4] Liquidity Position - At the end of the fourth quarter, CP had cash and cash equivalents of C$184 million, down from C$411 million in the previous quarter, while long-term debt decreased to C$19.94 billion from C$21.59 billion [5] Future Outlook - For 2026, CP anticipates core adjusted earnings per share to grow in the low double digits from 2025 actuals to C$4.61 per share, with revenue ton miles (RTMs) expected to increase in the mid-single digits [6] - Capital expenditures for 2026 are projected to be C$2.65 billion, with an expected core adjusted effective tax rate of 24.75% [6]

Uh, meantime, Lululemon earnings are out. Courtney Reagan has details from the report. Court.>> Yeah, John. And before I give you the details from the report, I have to let you know that CEO Kevin McDonald will be stepping down from Lululemon. There is going to be an extensive search, but in the meantime, the current CFO and chief commercial officer will step in to run as effective co-CEOs until a permanent successor has been named.McDonald has been with the company since 2018. And of course, as we've talke ...

Core Insights - Salesforce.com reported $10.26 billion in revenue for the quarter ended October 2025, marking an 8.6% year-over-year increase, with an EPS of $3.25 compared to $2.41 a year ago [1] - The reported revenue was in line with the Zacks Consensus Estimate, showing a slight surprise of -0.05%, while the EPS exceeded expectations by 14.04% [1] Financial Performance Metrics - Remaining performance obligation (RPO) - Current: $29.40 billion, exceeding the average estimate of $29.04 billion [4] - Remaining performance obligation (RPO) - Total: $59.50 billion, slightly above the estimated $59.05 billion [4] - Geographic Revenue - Americas: $6.7 billion, below the average estimate of $7.18 billion, but showing a year-over-year increase of 7.8% [4] - Geographic Revenue - Asia Pacific: $1.09 billion, surpassing the estimate of $1.02 billion, with a year-over-year growth of 9% [4] - Geographic Revenue - Europe: $2.47 billion, exceeding the average estimate of $2.05 billion, reflecting a 10.9% year-over-year increase [4] Revenue Breakdown - Revenues from Professional services and other: $533 million, below the average estimate of $541.51 million, representing a year-over-year decline of 5.7% [4] - Revenues from Subscription and support: $9.73 billion, slightly above the average estimate of $9.72 billion, with a year-over-year increase of 9.5% [4] - Revenues from Subscription and support - Agentforce Service: $2.5 billion, matching the estimate, with a year-over-year increase of 9.1% [4] - Revenues from Subscription and support - Agentforce Marketing and Agentforce Commerce: $1.36 billion, slightly below the estimate of $1.39 billion, with a year-over-year increase of 2% [4] - Revenues from Subscription and support - Agentforce 360 Platform, Slack and Other: $2.18 billion, exceeding the estimate of $2.07 billion, reflecting a year-over-year increase of 19.5% [4] - Revenues from Subscription and support - Agentforce Integration and Agentforce Analytics: $1.39 billion, below the estimate of $1.47 billion, with a year-over-year increase of 6.1% [4]

Core Insights - Werner Enterprises, Inc. (WERN) reported a third-quarter 2025 loss per share of 3 cents, missing the Zacks Consensus Estimate of earnings of 15 cents per share, compared to earnings of 15 cents per share in the same quarter last year [1][10] Financial Performance - Total revenues for the quarter were $771.5 million, exceeding the Zacks Consensus Estimate of $768.1 million, and reflecting a year-over-year increase of 3.5% driven by a $25.8 million (12%) rise in Logistics revenues, partially offset by a $3.0 million (1%) decline in Truckload Transportation Services (TTS) revenues, with a portion of the TTS decline attributed to a $3.3 million decrease in fuel surcharge revenues [2][10] - Adjusted operating income was reported at $10.91 million, a decrease of 50% year over year, with an adjusted operating margin of 1.4%, down 150 basis points from the previous year [3] - In the TTS segment, revenues fell 1% year over year to $519.78 million, with adjusted operating income dropping 63% to $8.95 million and an adjusted operating margin declining 300 basis points to 1.7%. Conversely, Logistics revenues increased 12% year over year to $232.58 million, with adjusted operating income rising over 100% to $4.16 million and an adjusted operating margin increasing 140 basis points to 1.8% [4][10] Liquidity and Capital Expenditure - As of September 30, 2025, Werner had cash and cash equivalents of $50.98 million, slightly down from $51.42 million at the end of the previous quarter. Long-term debt remained stable at $725 million. The company generated $44.1 million in cash from operations during the third quarter, with net capital expenditure amounting to $35.2 million [5] - No share repurchases were made in the third quarter, with 5.0 million shares remaining under the new share repurchase authorization as of September 30, 2025 [6] Outlook - For 2025, Werner anticipates TTS truck growth to decline from breakeven to 2%, down from a prior estimate of 1-4%. Net capital expenditure is now projected to be between $155 million and $175 million, revised from $145 million to $185 million. The company expects dedicated revenues per truck per week to rise from breakeven to 1.5%, up from a previous estimate of 0-3%. The full-year 2025 tax rate is now expected to be in the range of 26%-27%, revised from 25%-26% [7]

Core Insights - Avantor, Inc. is a global provider of mission-critical products and services in the life sciences and advanced technologies sectors, competing with major players like Thermo Fisher Scientific and Merck KGaA [1] Financial Performance - Avantor's third-quarter 2025 financial results were disappointing, with adjusted earnings per share (EPS) decreasing by 15.4% year-over-year to $0.22, missing the Zacks Consensus Estimate by 4.4% [3][6] - The company reported a GAAP loss per share of $1.04, compared to an EPS of $0.08 in the same quarter last year [3] - Revenues for the quarter totaled $1.62 billion, representing a 5.3% decline from the previous year and falling short of the Zacks Consensus Estimate by 1.6% [4][6] - Organic sales declined by 4.7%, with core segments also posting declines [4][6] Stock Performance and Guidance - Following the disappointing financial performance, Avantor's stock price plunged by 23.2% [5][6] - The company revised its full-year 2025 guidance, projecting EPS to be between $0.88 and $0.92, with organic sales expected to decrease by up to 3.5% [5] - JPMorgan Chase and Co. adjusted the price target for Avantor from $17.00 to $14.00 [5] Insider Activity - On October 30, 2025, SUMME GREGORY L, a director at Avantor, purchased 100,000 shares at $11.25 per share, increasing his total holdings to 300,000 shares [2]